You are here

Clinical Trials

PFS worse with bendamustine and rituximab in new study
Sotagliflozin may improve glucose control without increasing weight or hypoglycemia
Amicus won’t pursue wound-healing agent SD-101 for epidermolysis bullosa
Three sub-analyses parse results of EMPA-REG OUTCOME trial
ACR20 responses at two doses reach 65% and 56% at 12 weeks
Johnson & Johnson unit will focus on hepatitis B instead
New AstraZeneca, Amgen drug reduces exacerbations by up to 71%
Cellectis to amend protocols by reducing dose in hopes of resuming phase 1 studies
Effect of the drug’s accumulation in adipose tissue also unknown
Phase 1 trials of MEDI1341, an alpha-synuclein antibody, will begin by end of 2017
Kyprolis and dexamethasone reduced risk of death in relapsed or refractory patients
Longer-acting GLP-1 diabetes drug reports strong results in Sustain-7 trial
Antibody failed to meet primary endpoint in phase 3 trial
ZYN002 fails to meet primary and secondary endpoints
Durvalumab/tremelimumab combo fails to improve PFS compared to chemotherapy